Bringing more precise, minimally invasive treatment options for patients with complex vascular disease

Cooper University Health Care is among the first health systems in the United States to adopt the next-generation SEISMIQ Intravascular Lithotripsy System, an advanced intravascular lithotripsy technology that uses acoustic pressure waves to break up calcifications in the peripheral arteries and enhance vessel preparation prior to endovascular intervention.

Philip Batista, MD, a vascular surgeon and division head of vascular surgery at Cooper, recently performed Cooper's first case using the SEISMIQ system, using the technology to treat a patient with complex peripheral arterial disease.

The SEISMIQ system is designed to help physicians more easily guide catheters through blood vessels, treat blocked or hardened areas with greater precision, and maintain better control during complex vascular procedures. For patients, this may translate into safer, more precise procedures with improved outcomes and expanded access to minimally invasive treatment options.

"Technologies like SEISMIQ are helping us treat patients with hard-to-reach or hardened blood vessels in a less invasive way," said Dr. Batista, who also serves as associate professor of surgery at Cooper Medical School of Rowan University. "This system helps us prepare blood vessels more accurately before treatment and gives us another option for patients who may have had fewer choices in the past. Being among the first to use this technology at Cooper reflects our commitment to bringing advanced care to our patients."

Cooper University Health Care's vascular and endovascular surgery program provides comprehensive care for patients with complex blood vessel disorders, including aortic disease, carotid artery disease, and peripheral arterial and venous conditions. The program combines both minimally invasive endovascular techniques and traditional open surgical approaches to deliver individualized treatment based on each patient's condition and needs.

As an academic health system and regional referral center, Cooper offers advanced procedural capabilities, including a hybrid operating room environment and participation in national and international clinical research trials. This integration of clinical care and research enables the team to treat a high volume of complex cases while advancing new technologies and therapies in vascular surgery.

About Cooper University Health Care

Cooper University Health Care is a leading academic health system affiliated with Cooper Medical School of Rowan University. Cooper, headquartered in Camden, New Jersey, has revenues of more than $3 billion and an A+ credit rating from both S&P and Fitch Ratings.

Cooper has nearly 14,000 team members, including more than 2,200 nurses, more than 1,200 employed physicians representing 95 specialties and subspecialties, and more than 700 advanced practice providers.

Cooper operates MD Anderson Cancer Center at Cooper as well as three hospitals - its 663-bed flagship Cooper University Hospital in Camden, its 229-bed Cooper University Hospital Cape Regional in Cape May Court House, and Children's Regional Hospital in Camden.

Cooper University Hospital in Camden is the only Level 1 trauma center in South Jersey and the busiest in the region. The hospital has been recognized as a top-performing regional hospital by U.S. News & World Report's Best Hospitals annual survey for six years.

More than 2.54 million patients visit Cooper's facilities annually. Cooper's ambulatory network encompasses three outpatient surgery centers, seven urgent care centers, a wound care center, and more than 130 physician, physical therapy, and radiology offices extending from the Delaware River to the New Jersey shore.

Cooper was named one of America's Best Large Employers for 2026 by Forbes, ranking among the top 200 in the nation. Visit CooperHealth.org to learn more.

###